Author Archives: admin


Stem Cell Clinic > Articles by: admin

Value and Supply Side Analysis of Key Players of Cell Therapy Manufacturing Market – Cole of Duty

By Stell Cell Research

Prophecy Market Insights Cell Therapy Manufacturing market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges.

Initially, Cell Therapy Manufacturing report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cell Therapy Manufacturing market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

As we all are well aware of pandemic and we dont know what lies ahead once this COVID-19 Pandemic crises are over. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you with an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

The executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Cell Therapy Manufacturing market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Cell Therapy Manufacturing research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Cell Therapy Manufacturing market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Cell Therapy ManufacturingMarket Key Players:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/21

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Report Scope:

Europe

Asia Pacific

Latin America

Middle East & Africa

Some Important Questions Answered in the Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Therapy-Manufacturing-Market-21

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Original post:
Value and Supply Side Analysis of Key Players of Cell Therapy Manufacturing Market - Cole of Duty

Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And…

By Stem Cell Treatment

New Jersey, United States,- Latest update on Musculoskeletal Disorder Stem Cell Therapy Market Analysis report published with extensive market research, Musculoskeletal Disorder Stem Cell Therapy Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Musculoskeletal Disorder Stem Cell Therapy industry. With the classified Musculoskeletal Disorder Stem Cell Therapy market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Musculoskeletal Disorder Stem Cell Therapy market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Musculoskeletal Disorder Stem Cell Therapy market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Musculoskeletal Disorder Stem Cell Therapy Market growth opportunities in the industry.

Musculoskeletal Disorder Stem Cell Therapy Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Musculoskeletal Disorder Stem Cell Therapy market size, volume and value, as well as price data.

Musculoskeletal Disorder Stem Cell Therapy Market competition by top Manufacturers:

Musculoskeletal Disorder Stem Cell Therapy Market Classification by Types:

Musculoskeletal Disorder Stem Cell Therapy Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Musculoskeletal Disorder Stem Cell Therapy Market Report:

Cataloging the competitive terrain of the Musculoskeletal Disorder Stem Cell Therapy market:

Unveiling the geographical penetration of the Musculoskeletal Disorder Stem Cell Therapy market:

The report of the Musculoskeletal Disorder Stem Cell Therapy market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Musculoskeletal Disorder Stem Cell Therapy Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Musculoskeletal Disorder Stem Cell Therapy Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read more here:
Musculoskeletal Disorder Stem Cell Therapy Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And...

Pharmaxis granted orphan drug designation for PXS5505 by FDA for treatment of myelofibrosis – Proactive Investors Australia

By Stem Cell Treatment

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

() has been granted an orphan drug designation for its pan LOX inhibitor PXS-5505 for the treatment of myelofibrosis by the US Food and Drug Administration (FDA).

PXS5505 is an oral drug that inhibits all lysyl oxidase family members (LOX, LOXL1, 2, 3 & 4).

The compound successfully cleared preclinical safety including 6month toxicity studies and has shown significant reductions in fibrosis in invivo models of myelofibrosis and other cancers.

PXS5505 has shown to be well tolerated in phase 1 single and multiple ascending dose studies in humans with an excellent pharmacokinetic and pharmacodynamic profile.

Orphan designation qualifies the sponsor of the drug for various development incentives such as reduced regulatory fees and extended periods of market exclusivity.

Pharmaxis chief executive officer Gary Phillips said: We are very pleased with the FDA orphan drug designation for PXS5505.

Pharmaxis believes that the current treatments for myelofibrosis can be augmented by a panLOX inhibitor and be disease modifying in a market with high unmet need and significant deal values for programs with clinical proof of concept.

We expect to file an investigational new drug (IND) application with the FDA shortly and will provide an update on the clinical trial plans at that time.

Myelofibrosis is a rare cancer in which normal bone marrow tissue is gradually replaced with a fibrous scarlike material.

Over time, this leads to progressive bone marrow failure preventing the production of adequate numbers of red cells, white cells and platelets.

Myelofibrosis has a poor prognosis and limited therapeutic options.

Apart from a small group of patients eligible for stem cell transplantation, current standard of care are JAK1/2 inhibitors which provide mainly symptomatic relief but carry a risk of worsening blood cell counts.

A recent publication reported that Pharmaxis panLOX inhibitor compounds significantly decreased the bone marrow fibrotic burden in two different models of primary myelofibrosis.

Go here to see the original:
Pharmaxis granted orphan drug designation for PXS5505 by FDA for treatment of myelofibrosis - Proactive Investors Australia

Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis’ Proprietary POCare Technologies for the…

By Stell Cell Research

July 14, 2020 07:00 ET | Source: Orgenesis Inc.

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (Orgenesis or the Company), a pioneering global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announces that it has entered into a Collaboration Agreement with Educell Ltd., a premier European cell therapy company. Under the agreement, the parties plan to conduct one or more collaborative cell-based research projects aligned with local medical centers.

The companies will leverage the Orgenesis Cell and Gene Therapy (CGT) Biotech Platform which includes point of care (POCare) Networks, POCare Therapeutics and a POCare Technologiessuite of proprietary and in-licensed technologies that have been engineered to create customized processing systems. The agreement is part of the Orgenesis strategy of growing and expanding the POCare Network, which includes leading hospitals and research institutes around the world. The first collaboration under the agreement will focus on the clinical development of CAR-T and whole cell-based vaccine platform for use in cancer immunotherapies.

Vered Caplan, CEO of Orgenesis, stated, This latest collaboration with Educell expands our activities in Europe and we believe that it should help us launch our therapies into additional European hospitals, as well as help Educell commercialize their therapies around the world. We also believe that this collaboration reinforces the significant value proposition and flexibility of our CGT Biotech Platform. We look forward to benefiting from the expertise of Educell as we seek to expand our automated T-cell culturing approach into clinical validation and commercialization phases.

Dr Miomir Kneevi, CEO of Educell, commented, We are excited to team with Orgenesis to potentially advance these breakthrough therapies into clinical trials using cutting edge technologies. This collaboration reflects our commitment to bringing new, effective and affordable cell and gene therapy products to cancer patients worldwide while highlighting Educells ability to ensure safety in the process and help to reduce overall manufacturing costs.

Together, the companies are working to address significant unmet market needs for producing novel cell therapies in a cost effective, high quality and scalable manner. The joint clinical development program seeks to provide safe, simplified, and cost-effective processing in an automated and controlled environment from start to finish with minimal operator intervention.

About Educell Educell Ltd, established 1997, is a company focusing on the development of cell therapy products and is a registered cell and tissue establishment. The company is preparing cell therapy products for the treatment of articular cartilage, vesicouretral reflux, regeneration of bone tissue and treatment of immunological disorders, which are in use within the University Medical Centre Ljubljana and other clinical institutions in Slovenia under the hospital exemption rule supervised by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia. The companys R&D department is dedicated to the development of innovative cell therapy products and also to the development of medical devices that enable stem cell isolation and application in the operation theatre.

Educells ImmunoArt cell therapy product was developed in 2014 and is based on ex vivo expanded allogeneic mesenchymal stromal/stem cells (MSC) isolated from bone marrow. Its immunomodulatory capacity has already been proven in the clinic for the treatment of graft versus host disease (GvHD) and Chrons disease. Additional information is available at: https://www.educell.si/en/

About Orgenesis Orgenesis is a pioneering global biotech company which is unlocking the full potential of personalized therapies and closed processing systems through its Cell & Gene Therapy Biotech Platform, with the ultimate aim of providing life changing treatments at the Point of Care to large numbers of patients at low cost. The Platform consists of: (a) POCare Therapeutics, a pipeline of licensed cell and gene therapies (CGTs), and proprietary scientific knowhow; (b) POCare Technologies, a suite of proprietary and in-licensed technologies which are engineered to create customized processing systems for affordable point of care therapies; and (c) POCare Network, a collaborative, international ecosystem of leading research institutes and hospitals committed to clinical development and supply of CGTs at the point of care. By combining science, technologies and a collaborative network, Orgenesis is able to identify the most promising new therapies and provide a pathway for them to reach patients more quickly, more efficiently and at scale, thereby unlocking the power of cell and gene therapy for all. Additional information is available at: http://www.orgenesis.com.

Notice Regarding Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to effectively use the net proceeds from the sale of Masthercell, our ability to achieve and maintain overall profitability, the development of our POCare strategy, the sufficiency of working capital to realize our business plans, the development of our transdifferentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our technology not functioning as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31 2019, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact for Orgenesis: Crescendo Communications, LLC Tel: 212-671-1021 Orgs@crescendo-ir.com

View original post here:
Orgenesis to Collaborate with Educell to Conduct Clinical Validation of Cell Therapies Using Orgenesis' Proprietary POCare Technologies for the...

Cell Separation Technologies Market: Analysis of Technological Advancement in Coming Year 2020-2029 – Cole of Duty

By Stell Cell Research

Prophecy Market Insights Cell Separation Technologies market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges.

Initially, Cell Separation Technologies report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Cell Separation Technologies market analysis is provided for the international markets including development trends, competitive landscape analysis, geography, end-users, applications, market share, COVID-19 analysis, and forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/1613

As we all are well aware of pandemic and we dont know what lies ahead once this COVID-19 Pandemic crises are over. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you with an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

The executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Cell Separation Technologies market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Cell Separation Technologies research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Cell Separation Technologies market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Stakeholders Benefit:

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Cell Separation TechnologiesMarket Key Players:

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/1613

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Report Scope:

Europe

Asia Pacific

Latin America

Middle East & Africa

Some Important Questions Answered in the Market Report are:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Cell-Separation-Technologies-Market-1613

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

Go here to read the rest:
Cell Separation Technologies Market: Analysis of Technological Advancement in Coming Year 2020-2029 - Cole of Duty

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R) – BioSpace

By Stem Cell Medicine

GOLDEN, CO / ACCESSWIRE / July 14, 2020 / Vitro Diagnostics, Inc. (OTC PINK:VODG), dba Vitro Biopharma, jointly with GIOSTAR - a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science - announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells.

This patient was admitted to an emergency room with classic COVID-19 symptoms in late April and had several comorbidities prior to admission. While intubated in the intensive care unit (ICU), the patient's condition worsened using the standard of care and treatment with convalescent plasma. The patient's kidney and liver function began to fail, requiring dialysis. Additionally, the patient experienced sepsis and a stroke while in the ICU and was comatose for almost 7 weeks.

Following the treatment with AlloRx Stem Cells, the patient experienced resolution of multiple organ failure, recovery from coma, and restoration of neurological, pulmonary, liver and renal function. The patient was removed from assisted respiration and dialysis. The patient now eats, drinks, speaks, and has regained motor function. Measures of inflammation that were elevated at admission and rose during ICU treatment, returned to normal levels. The patient has recently been discharged from ICU and is currently undergoing physical therapy to recover from the stroke suffered while in the ICU.

This study was authorized by the FDA through an Investigational Drug Application (eIND) for emergency use under expanded access granted to GIOSTAR, Vitro Biopharma's partner in stem cell therapy for COVID-19 using AlloRx Stem Cells as the therapeutic agent. GIOSTAR Medical Director Dr. Prabhat Soni oversaw the clinical management of the patient and all related clinical/regulatory issues. Vitro Biopharma is pleased to partner with GIOSTAR to provide expanded offerings of AlloRx Stem Cell COVID-19 therapy to its expanding global clientele, while at the same time expanding treatment to US COVID-19 patients through eIND and pending INDs.

Dr. Anand Srivastava, MS, PhD, GIOSTAR's Chairman and Chief Scientific Officer said "COVID-19 infection triggers the spectrum of inflammatory cytokines, which results in severe COVID-19 induced pneumonia and acute respiratory distress syndrome (ARDS), followed by multiple organ failure. Utilizing the natural immunomodulatory character of AlloRx Stem Cell (Mesenchymal Stem Cells or MSCs) may be one of the best ways to neutralize COVID-19 induced inflammatory cytokines actions on lung and other organs to rescue the patients suffering from COVID-19 infection."

Dr Jack Zamora, MD, Vitro Biopharma's Chief Medical Advisor said, "The miraculous recovery of our first critically ill COVID-19 patient using AlloRx Stem Cells bring great hope in these troubling times. We continue with our FDA IND application with even greater hope of delivering a promising treatment to US patients, and through GIOSTAR, we have reached out to various Ministries of Health worldwide with this promising news."

"We are pleased to have achieved this milestone that was based on thorough understanding of the science of stem cell biology," said Dr Jim Musick, CEO of Vitro Biopharma. "While regeneration of destroyed cells is a common effect of stem cell therapy, stem cells also regenerate damaged cells by various regenerative processes that restore normal organ function. The results of this case support the further study of AlloRx Stem Cell Therapy for COVID-19 patients and other conditions characterized by acute respiratory distress that are ultimately related to the inflammatory cytokine cascade that is neutralized by AlloRx Stem Cells. Our therapy appears to have significant therapeutic application in treatment of multi-organ failure related to COVID-19 infections."

"The results with this patient are quite remarkable," stated Dr. Soni, Chief Medical Officer, Giostar, Inc. "It is highly likely that the patient would have died without stem cell therapy, because the combination of organ failure and comorbidities yielded a very poor prognosis. We are pleased to partner with Vitro Biopharma and look forward to providing this therapeutic option for slowing the pandemic on a global scale."

About Vitro Biopharma:

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands http://www.DVCStem.com. We have a recently approved clinical trial using our AlloRx Stem Cells to treat musculoskeletal conditions at The Medical Pavilion of the Bahamas http://www.tmp-bahamas.com in Nassau.

Vitro Biopharma has a proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients and other conditions including multiple sclerosis, OA, Chrohn's disease and numerous medical conditions that are under-treated by the current standard of care. Our cGMP manufacturing is CLIA, ISO9001, ISO13485 certified and we are FDA registered. Our stem cells have been shown to be safe and effective in Phase I clinical trials.

CONTACT:

Dr. James Musick Chief Executive Officer Vitro Biopharma (303) 550-2778 E-mail: jim@vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/597400/Critically-ill-COVID-19-Patient-Successfully-Treated-with-Vitro-Biopharmas-AlloRx-Stem-CellsR

Go here to read the rest:
Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma's AlloRx Stem Cells(R) - BioSpace

Global Induced Pluripotent Market 2020 Analysis with COVID-19 Effects|Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol…

By Stem Cell Medicine

Few of the major competitors currently working in the induced pluripotent market are Bristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Download Sample PDF Copy of Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-market

Key questions answered in the Global Induced Pluripotent Market report include:

Market Drivers

Market Restraints

Access Complete Report @ https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-market

Segmentation: Global Induced Pluripotent Market

By Product Category

By Cell Type

By Application

By End-User

By Geography

Key Developments in the Market:

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:[emailprotected]

More:
Global Induced Pluripotent Market 2020 Analysis with COVID-19 Effects|Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol...

COVID-19 Impact ON of Stem Cell Therapy Market to Register Impressive Growth by 2027 | Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon…

By Stell Cell Research

Coherent Market Insights Latest released the research study on Global Stem Cell Therapy Market, which offers a detailed overview of the factors influencing the global business scope. Stem Cell Therapy Market research report shows the latest market insights, current situation analysis with upcoming trends, and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Stem Cell Therapy Market. The study covers the emerging players data, including competitive landscape, sales, revenue, and global market share of top manufacturers.

To learn more about this report, request a sample copy: https://www.coherentmarketinsights.com/insight/request-sample/2848

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Stem Cell Therapy Market and Competitive Analysis:

Know your current market situation! Not just new products but existing products are given the ever-changing market dynamics. The study allows market professionals to stay tuned with the latest trends and segment performance where they can see a rapid market share drop. Identify who you really compete within the marketplace, with Market Share Analysis correlate your market position, % Market Share, and Segmented Revenue.

Some Key Players from complete research coverage: Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

(*Note: Other Players can be added per Request)

Additionally, Section on Historical Stem Cell Therapy Market Scenario, Market Entropy to Race Aggressiveness, and Patent Analysis* is covered along with Competitors SWOT, Product Specifications, and Peer Comparison including variables such as Gross Margin, Total Revenue, Segment Revenue, Employee Size, Net Profit, Total Assets, etc.

Segmentation and Targeting:

Essential demographic, geographic, psychographic, and behavioural information about business segments in the Stem Cell Therapy market is targeted to aid in determining the features company should encompass in order to fit into the business requirements.

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase Global Stem Cell Therapy Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/2848

** For the global report, countries by region that are available in the study:

North America (United States, Canada & Mexico)

Asia-Pacific (Japan, China, India, Australia, New Zealand, South Korea, Taiwan, Singapore, Thailand, Indonesia & Philippines, etc.)

Europe (Germany, UK, France, Spain, Italy, Netherlands, Belgium, Austria, Poland, Switzerland, Bulgaria and Rest of Europe, etc.)

Central & South America (Brazil, Argentina, Colombia & Chile, etc.)

Middle East & Africa (United Arab Emirates, Saudi Arabia, Nigeria, South Africa, etc.)

Stem Cell Therapy Market Product/Service Development:

Knowing why products/services fit the need of clients and what modification would make the product more attractive. Approaches such as focus group utilizing User Testing and Experience Research. Consumer side analysis always helps to correlate demand preferences with innovation.

Market Scope & Target with Key Findings / Objectives:

How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020?

Analyst at Coherent Market Insights has conducted a special survey and has connected with opinion leaders and industry experts from the various regions to minutely understand the impact on growth as well as local reforms to fight the situation. A special chapter in the study presents Impact Analysis of COVID-19 on Global Stem Cell Therapy Market along with tables and graphs related to various countries and segments showcasing impact on growth trends.

Stem Cell Therapy Market Key Business Segments Growth & % Share May See a Paradigm Shift

Various segments analyzed and sized in this study by application/end-users displays the potential growth and various shift for period 2014 to 2026. The changing dynamics supporting the growth makes it critical for businesses in this space to keep abreast of the moving pulse of the market. Check which segment will bring in healthy gains adding significant momentum to overall growth., Industry Segmentation (Public, Commercial ), Channel (Direct Sales, Distributor) Segmentation have been considered for segmenting the Stem Cell Therapy market by type.

Additionally, the study provides an in-depth overview of country-level break-up classified as potentially high growth rate territory, countries with the highest market share in past and current scenarios. Some of the regional break-ups classified in the study.

Trade dispute will continue, who is staying up in Competition: An Unsold Story

Due to pandemic, significant economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Stem Cell Therapy market. Negotiations between the 2-largest global economies will continue in 2020, shaping all the uncertainty and worry-making still some emerging players are tapping the highest growth rate and establishing its market share whereas reliable giants of Global Stem Cell Therapy Market still tuned with their strategic moves to challenge all competition. How Key Players of the Global Stem Cell Therapy Market are Identified and what all Scenarios are considered while profiling players.

Disruptive competition tops the list of industry challenges

Revenue Monetization models, customer experience and cost of business making

Top innovative drivers, Strategic moves, etc.

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Need a discount?

Request discount for this report @https://www.coherentmarketinsights.com/insight/request-discount/2848

Note: *The discount is offered on the Standard Price of the report.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Southeast Asia.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact US Mr. Shah Email:[emailprotected] Phone: US +1-206-701-6702/UK +44-020 8133 4027

Excerpt from:
COVID-19 Impact ON of Stem Cell Therapy Market to Register Impressive Growth by 2027 | Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon...

Stem Cell Drugs Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 – 3rd Watch…

By Stell Cell Research

New Jersey, United States,- Latest update on Stem Cell Drugs Market Analysis report published with extensive market research, Stem Cell Drugs Market growth analysis, and forecast by 2026. this report is highly predictive as it holds the overall market analysis of topmost companies into the Stem Cell Drugs industry. With the classified Stem Cell Drugs market research based on various growing regions, this report provides leading players portfolio along with sales, growth, market share, and so on.

The research report of the Stem Cell Drugs market is predicted to accrue a significant remuneration portfolio by the end of the predicted time period. It includes parameters with respect to the Stem Cell Drugs market dynamics incorporating varied driving forces affecting the commercialization graph of this business vertical and risks prevailing in the sphere. In addition, it also speaks about the Stem Cell Drugs Market growth opportunities in the industry.

Stem Cell Drugs Market Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including Stem Cell Drugs market size, volume and value, as well as price data.

Stem Cell Drugs Market competition by top Manufacturers:

Stem Cell Drugs Market Classification by Types:

Stem Cell Drugs Market Size by End-user Application:

Listing a few pointers from the report:

The objective of the Stem Cell Drugs Market Report:

Cataloging the competitive terrain of the Stem Cell Drugs market:

Unveiling the geographical penetration of the Stem Cell Drugs market:

The report of the Stem Cell Drugs market is an in-depth analysis of the business vertical projected to record a commendable annual growth rate over the estimated time period. It also comprises of a precise evaluation of the dynamics related to this marketplace. The purpose of the Stem Cell Drugs Market report is to provide important information related to the industry deliverables such as market size, valuation forecast, sales volume, etc.

Major Highlights from Table of contents are listed below for quick lookup into Stem Cell Drugs Market report

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the original post:
Stem Cell Drugs Market Size By Product Analysis, Application, End-Users, Regional Outlook, Competitive Strategies And Forecast Up To 2026 - 3rd Watch...

What’s next for Tony Fauci, if the White House continues to sour on him? – STAT

By Embryonic Stem Cells

WASHINGTON The White House in recent days has accelerated an effort that President Trump began months ago: Openly discrediting the guidance of Anthony Fauci, the countrys top infectious diseases researcher.

Trump accused Fauci of making a lot of mistakes since the onset of the Covid-19 pandemic in a recent interview, justifying his continued disagreements with the veteran scientist on issues as routine as the number of new coronavirus cases. He also said he disagreed with Faucis assessment that the U.S. was handling the crisis poorly to other nations which, given the 60,000-plus Americans being diagnosed with the disease each day, is a simple reality. On Sunday, the Washington Post reported the White House had begun circulating a list of Faucis early predictions and guidance surrounding the Covid-19 pandemic that many, in hindsight, have labeled as overly optimistic, though several lacked context.

The latest broadsides have reignited fears that Trump could take far more drastic action to limit Faucis public health power and platform or even remove him from his post, the way Trump has unceremoniously axed so many other federal officials.

advertisement

Faucis future role in the U.S. governments pandemic response will follow one of three paths. Though Trump cant easily fire him, administration officials could remove him from his post leading the National Institute of Allergy and Infectious Diseases and reassign him elsewhere in government. Trump could also attempt to formally bar Fauci from conducting public briefings or interviews, effectively silencing one of the administrations most recognizable public health experts.

Or Trump could continue to quietly diminish Faucis role and subtly limit his public platform as he has for months.

advertisement

Faucis role in public outreach has visibly diminished since spring, when he would regularly accompany Trump to daily White House coronavirus task force press briefings. His public role has since been reduced to sporadic appearances on podcasts, at scientific gatherings, or in print news stories. Fauci said recently he hasnt briefed the president since June.

Even at the since-discontinued briefings, Trump would challenge Fauci, once admitting we disagree a little bit on lack of evidence surrounding hydroxychloroquine, the malaria drug, in preventing Covid-19, allowing that his view was just a feeling.

For now, however, the White House has insisted that Fauci remains in good standing and is not in jeopardy of losing his job. Trump even boasted of his very good relationship with Fauci on Monday.

Outside experts, however, feel that as long as Fauci continues to speak the truth on the realities of the pandemic, hell keep making enemies within the administration.

If they do punish Fauci for telling the truth, then where are we? said Elias Zerhouni, the former NIH director who famously testified to Congress that former president George W. Bushs ban on scientific use of embryonic stem cells was stifling research. You can ignore it, you can say I dont take [your advice] into account, I changed my mind, Im the policy maker. But dont say youre going to punish the messenger.

Below, STAT walks through the possible futures for Fauci and why some are likelier than others.

The most dramatic and least likely move: Trump could try to fire Fauci.

But federal law prevents the president from firing most government employees without cause.

Tony Fauci is not a presidential appointee, Zerhouni said. Hes a civil [servant] for 35, 40 years. So you cant really fire him from the government thats not in the powers of the president.

But if push came to shove, Trump could almost certainly order Faucis superiors health secretary Alex Azar or NIH chief Francis Collins to reassign him to a different role within the Department of Health and Human Services.

Theres precedent for such a move even during the Covid-19 pandemic. In late April, the Trump administration abruptly made a leadership change at BARDA, an agency explicitly tasked with keeping the nation prepared for a pandemic or bioterrorism.

The agencys ousted leader, Rick Bright, was reassigned to a post at NIH focused on developing diagnostic tests. He soon claimed in a whistleblower lawsuit that his reassignment was retribution for his opposition to the presidents enthusiasm for hydroxychloroquine.

Zerhouni stressed that he does not believe Trump would move to reassign Fauci. But if he did, he said, it would put Azar and Collins in a difficult position.

It would be like the Saturday Night Massacre, to be honest with you, Zerhouni said, referencing the infamous 1973 night when former president Richard Nixon ordered his attorney general to fire a special prosecutor investigating the White House, only for the attorney general and his deputy to resign in protest instead of carrying out his order.

If they do that, a lot of other people would resign, he said.

A slightly less severe, though no less noticeable, step: Trump could cut off Fauci from making any media appearances whatsoever.

Already in March, White House officials started requiring federal health experts to get their approval for any public speaking engagement. And Faucis seen his time limited as the pandemic has dragged on, especially after the administrations Covid-19 task force stopped conducting daily briefings.

Its not an out-of-the-ordinary arrangement; NIH leadership had to clear its media appearances with the White House in Zerhounis time too, the former NIH director said.

You have to go by the rules of communication in the government, he said. Its very typical.

But Trump has, at least in one case, taken things much farther. In late February, Nancy Messonnier, a high-ranking Centers for Disease Control and Prevention official, delivered a stark warning in a press briefing: The agency expected the coronavirus would soon begin spreading through American communities, and the disruptions to daily life could be severe.

The remarks now seem prescient, even unreasonably calm. But when they were published, stock markets nosedived, and Trump was enraged, and reportedly advocated for firing Messonnier. The end result has been functionally similar, at least in terms of Messonniers public-facing role: She has not briefed reporters, or spoken publicly in any way, since.

Thats far more concerning, Zerhouni said.

The fact that they dont let you for a long time that is something else. I never had that, he said. I always cleared it with the White House and HHS and it was usually okay, and I dont recall an instance where I was censored to not talk.

Even if the White House did bar Fauci from any future media appearances, he could still continue in arguably his most important function: Helping to oversee the development of coronavirus vaccines and therapeutics. Messonnier, in fact, has presumably done much the same at CDC, returning to run an agency office focused on vaccines and respiratory diseases.

Attempting to silence Fauci from his role as a public health messenger, however, seems both difficult and unlikely: He is well liked and trusted among Americans, effectively a household name.

Fauci, who has served six presidents and led the National Institute on Allergy and Infectious Disease since 1984, isnt necessarily the natural face of public health. His main job at NIAID is to oversee nearly $6 billion in grants and in-house research conducted into vaccines and medicines.

Faucis role, technically, is that of a researcher not that of a public health advisor. Its only after decades playing a leading role advising presidents like Ronald Reagan during the HIV epidemic and Barack Obama during the Ebola outbreak in Western Africa that the public has come to view him as a key part of any presidents public health apparatus a role that could easily be filled by CDC or others within the federal health department.

But because Faucis role as a public spokesman is not a formal part of his job, its also easy for Trump and other federal officials to limit how much of that work falls to him.

Experts view this as the most likely scenario, in large part because it is the one that is currently happening. And despite the low-grade attacks, former NIH director Harold Varmus argued its a tolerable status quo as long as decisions about what research the agency funds and conducts doesnt become more politicized, too.

So far, [criticism of Fauci] has not affected the way NIH conducts and supports scientific research, he said. On the other hand, certainly, the government should have a representative who speaks the truth about whats going on and no one is as well equipped as Tony Fauci to do that.

Washington Correspondent

Lev Facher covers the politics of health and life sciences.

Trending

Pharma trade group scolds Gilead again for misleading information

Pharma trade group scolds Gilead again for misleading information about a rival HIV drug

Trial of Moderna Covid-19 vaccine delayed, investigators say, but

Trial of Moderna Covid-19 vaccine delayed, investigators say, but July start still possible

We dont actually have that answer yet: WHO clarifies

We dont actually have that answer yet: WHO clarifies comments on asymptomatic spread of Covid-19

Recommended

How to fix the Covid-19 dumpster fire in the

How to fix the Covid-19 dumpster fire in the U.S.

Pickup truck medicine: saving primary care during Covid-19

Pickup truck medicine: saving primary care during Covid-19

In the NICU, both parents are essential and need

In the NICU, both parents are essential and need to be at their childs bedside

Read more:
What's next for Tony Fauci, if the White House continues to sour on him? - STAT

→←